Advanced search
Publication Cover
COPD: Journal of Chronic Obstructive Pulmonary Disease Volume 9, 2012 - Issue 3
Submit an article Journal homepage
1,223
Views
16
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Using Post-bronchodilator FEV1 is Better Than Pre-bronchodilator FEV1 in Evaluation of COPD Severity

Chiung-Zuei ChenDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
,
Chih-Ying OuDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
,
Wen-Ling WangDepartment of Nursing, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
,
Cheng-Hung LeeDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
,
Chien-Chung LinDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
,
Han-Yu ChangDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
&
Tzuen-Ren HsiueDepartment of Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TaiwanCorrespondence[email protected]
 show all
Pages 276-280 | Published online: 23 Feb 2012

References

  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2006 updated. Bethesda, MD: National Heart, Lung and Blood Institute/World Health Organization.
  • Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:14–20.
  • Ferrer M, Alonso J, Morera J, Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127:1072–1079.
  • Dewan NA, Rafique S, Kanwar B, Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest 2000; 117:662–671.
  • Friedman M, Serby CW, Menjoge SS, Wilson JD, Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635–641.
  • Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991; 1:340–345.
  • Oga T, Nishimura K, Tsukino M, Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:544–549.
  • Domingo-Salvany A, Lamarca R, Ferrer M, Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680–685.
  • Celli BR, Cote CG, Marin JM, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005–1012.
  • Puhan MA, Garcia-Aymerich J, Frey M, Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374:704–711.
  • Briggs A, DPhil BA, Spencer M, Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008; 68(1):71–79.
  • Blonshine S, Mottram CD, Wanger J. Pulmonary Function Laboratory Management and Procedure Manual, 2nd ed. American Thoracic Society, New York, 2005.
  • Chen CZ, Lin CC, Lee CH, Chang HY, Hsiue TR. Small airways obstruction syndrome in clinical practice. Respirology 2009; 14:393–398.
  • Calverly PM, Anderson JA, Celli BR, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775–789.
  • Tashkin DP, Celli BR, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543–1554.
  • Guell R, Casan P, Belda J, Lomg-term effects of outpatient rehabilitation of COPD. A randomized trial. Chest 2000; 117:976–983.
  • Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-yaer survival than airway obstruction in patients with COPD. Chest 2002; 121:1434–1440.
  • Schols AM, Soeters PB, Dingemans AM, Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151–56.
  • Almagro P, Salvado M, Garcia-Vidal C, recent improvement in long-term survival after a COPD hospitalization. Thorax 2010; 65: 298–302.
  • Roberts CM, Lowe D, Bucknall CE, Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57:137–141.
  • Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and motality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60:925–931.
  • Sterk PJ. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 2004; 23:497–498.
  • Johannessen A, Omenaas ER, Bakke PS, Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005; 60:842–847.
  • Ashley F, Kannel WB, Sorlie PD, Pulmonary function: relation to aging, cigarette habit, and mortality. Ann Intern Med 1975; 82:739–745.
  • Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke OS, Murkve O. Risk of over diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117–1122.
  • Vestbo J, Lande P. Can GOLD stage 0 provide information or prognostic value in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:329–332.
  • De Marco R, Accordini S, Cerveri I, An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59:120–125.
  • Kerstjens HA. The GOLD classification has not advanced understanding of COPD. Am J Respir Crit Care Med 2004; 170:212–213.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.